iA Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

iA Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Buy	+9,166	New	+$1.36M	0.02%	291
2026 Q1	–	Sell	-5,800	Closed	-$823K	–	435
2025 Q4	$823K	Buy	5,800 +585	+11%	+$84.8K	0.01%	308
2025 Q3	$732K	Buy	+5,215	New	+$707K	0.01%	319
2024 Q4	–	Sell	-2,652	Closed	-$306K	–	486
2024 Q3	$306K	Buy	+2,652	New	+$364K	0.01%	440
2024 Q2	–	Sell	-1,410	Closed	-$194K	–	503
2024 Q1	$194K	Sell	1,410 -177	-11%	-$24.2K	﹤0.01%	440
2023 Q4	$209K	Buy	+1,587	New	+$183K	﹤0.01%	431

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

iA Global Asset Management's NBIX Position: Q2 2026 in Review

iA Global Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 9,166 shares worth $1.54M. The stake represents 0.02% of the portfolio and ranks #291 among its holdings. This is a return to the name: iA Global Asset Management previously reported a position in NBIX as recently as Q4 2025.

iA Global Asset Management first reported a position in NBIX in Q4 2023 and has held it in 6 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

iA Global Asset Management held 9,166 shares of Neurocrine Biosciences worth $1.54M as of Q2 2026.
Neurocrine Biosciences was a new iA Global Asset Management position in Q2 2026.
Neurocrine Biosciences made up 0.02% of iA Global Asset Management's portfolio in Q2 2026, its #291 holding.
iA Global Asset Management first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 6 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on iA Global Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.